Related Experiment Videos
[Ziprasidone-augmentation of clozapine]
Mathias Zink1, Evelyn Mase, Harald Dressing
1Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Mannheim. zink@kv.zi-mannheim.de
Psychiatrische Praxis
|July 10, 2004
Summary
This case study shows that combining clozapine with ziprasidone effectively treated treatment-resistant schizophrenia. This augmentation strategy improved both positive and negative symptoms while managing side effects.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Treatment-resistant schizophrenia often requires combination therapy with atypical antipsychotics.
- Standard monotherapies like olanzapine, risperidone, and quetiapine can be insufficient for some patients.
Observation:
- A 35-year-old male with paranoid schizophrenia showed persistent symptoms despite trials of olanzapine, risperidone, and quetiapine.
- Clozapine improved positive symptoms but negative symptoms and side effects persisted, impacting compliance.
Findings:
- Augmenting clozapine with ziprasidone led to remission of paranoid delusions and amelioration of negative symptoms.
- The combination therapy allowed for a reduced clozapine dosage and improved the patient's affective deficits.
- While transient hyperprolactinemia and sexual dysfunction occurred, the patient reported high satisfaction with symptom control.
Implications:
- The combined use of ziprasidone and clozapine presents a neurobiologically plausible strategy for managing complex schizophrenia cases.
- This augmentation may reduce adverse effects associated with higher clozapine doses.
- Further prospective studies are warranted to establish the risk-benefit profile of this combination therapy in treatment-resistant schizophrenia.